Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus (Q40498246)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus (English)

1 reference

Europe PubMed Central

21 September 2017

Orthonairovirus haemorrhagiae

0 references

Rift Valley fever phlebovirus

0 references

Hantaan River virus

1 reference

based on heuristic

inferred from title

Rift Valley fever

1 reference

based on heuristic

inferred from title

tick-borne encephalitis

1 reference

based on heuristic

inferred from title

tick-borne encephalitis virus

object named as

tick-borne encephalitis virus

1 reference

based on heuristic

inferred from title

Rift Valley fever virus

object named as

Rift Valley fever virus

1 reference

based on heuristic

inferred from title

object named as

Anita K McElroy

3

0 references

object named as

Jay W Hooper

5

0 references

author name string

Kristin Spik

1

1 reference

Europe PubMed Central

21 September 2017

Amy Shurtleff

2

1 reference

Europe PubMed Central

21 September 2017

Mary C Guttieri

4

1 reference

Europe PubMed Central

21 September 2017

Connie SchmalJohn

6

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

22 August 2005

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

24

1 reference

Europe PubMed Central

21 September 2017

21

1 reference

Europe PubMed Central

21 September 2017

4657-4666

1 reference

Europe PubMed Central

21 September 2017

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Hantaviruses: A Global Disease Problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

More deaths from Rift Valley fever in Saudi Arabia and Yemen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Immunogenicity and reactogenicity of a highly purified vaccine against tick‐borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Evaluation of tick-borne encephalitis DNA vaccines in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Hantaan virus infection in suckling mice: virologic and pathologic correlates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.08.034

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40498246&oldid=1899383699"